现代资讯现代实验室装备网
全国服务热线
400-100-9187、0731-84444840

BCEIA2023学术报告会大会报告人专题(五)

   2023-06-27 476
核心提示:马光辉中国科学院院士美国医学与生物工程院(AIMBE)fellow中国科学院过程工程研究所研究员生化工程国家重点实验室主任中国颗粒
       马光辉

中国科学院院士

美国医学与生物工程院(AIMBE)fellow

中国科学院过程工程研究所研究员

生化工程国家重点实验室主任

中国颗粒学会副理事长

中国化学会会士

中国化工学会会士

中国微米纳米技术学会会士

中国化工学会生物化工专业委员会副主任委员

中国生物工程学会生物基材料专业委员会主任委员


报告题目:新型分离介质的制备和蛋白药/疫苗纯化应用
Preparation of Novel Microspheres for Protein / Vaccine Separation Application

Polysaccharide particles such like agarose particles have been widely used in protein separation and purification as chromatographic packing materials by biological scientists and in industry. However, the limitation of conventional agarose particles is that the separation resolution is limited due to their broad size distribution. Furthermore, the particles with large size are usually used for industrial separation and purification to avoid the increase of back-pressure, which also limit the separation resolution. On the other hand, the particulate vaccine such like virus-like particle (VLP) has attracted more and more attention, conventional agarose particles with small pore size not only limited the adsorption of VLP, but also enhanced the disassociation of VLP, resulting very low activity recovery of VLP.We have developed a novel membrane process to prepare uniform agarose particle. By this technique we can control the CV (coefficient of variation) value which representing the size distribution around 15%, and we can prepare small uniform particles with high agarose concentration. Therefore, we can use small particles instead of large particles, and increase the separation resolution and flow rate of chromatography.  We have developed a new process to prepare giga-porous particle with pore size controllable between 100nm to 500 nm, and we found that it not only increased the loading amount of VLP, but also avoided the disassociation of VLP. This was because large pore size weakened the multi-site interaction between VLP and pore. This novel particle has been used for production of particulate vaccine instead of ultra-high speed centrifugation technique, much higher recovery was achieved.


个人简介
马光辉,中国科学院院士,美国医学与生物工程院(AIMBE)fellow,生化工程国家重点实验室主任。国家杰出青年获得者,基金委创新群体首席,中国颗粒学会副理事长,中国化学会会士、中国化工学会会士、中国微米纳米技术学会会士、中国化工学会生物化工专业委员会副主任委员、中国生物工程学会生物基材料专业委员会主任委员。研究方向为均一生物微球和微囊的制备及其在生化工程和医学工程中的应用,研究和开发用于生化分离、药物载体、免疫佐剂(疫苗递送系统)、细胞培养微载体、酶固定化载体等创新产品。在Nat. Mater., Sci. Transl. Med., Nat. Nanotechnol., Nat. Biomed. Eng., Sci. Adv., Nat. Commun., JACS, Adv. Mater.等国际著名学术期刊上发表SCI论文500余篇。出版中英文专著12部,撰写学术书章节22篇。中国发明专利授权81项,国际专利授权12项,专利技术和产品在国内外500多家单位得到应用。获国家技术发明二等奖、北京市科学技术一等奖、中国化工学会科学技术奖基础研究成果奖一等奖、中国颗粒学会自然科学奖一等奖、中国石油和化学工业联合会技术发明一等奖、侯德榜化工科技创新奖、“中国科协全国优秀科技工作者”称号。


 
反对 0举报 0 收藏 0 打赏 0
 
更多>同类资讯
推荐图文
推荐资讯
点击排行